Recro Pharma Stock Price, News & Analysis (NASDAQ:REPH)

$8.30 -0.40 (-4.60 %)
(As of 02/19/2018 04:54 AM ET)
Previous Close$8.30
Today's Range$8.29 - $8.90
52-Week Range$5.81 - $10.59
Volume166,435 shs
Average Volume117,181 shs
Market Capitalization$158.75 million
P/E Ratio-3.79
Dividend YieldN/A
Beta-0.6

About Recro Pharma (NASDAQ:REPH)

Recro Pharma logoRecro Pharma, Inc. is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company's lead product candidate is an injectable form of meloxicam. Its product candidates for pain indications include injectable meloxicam, a product candidate in development for the treatment of acute post-operative pain; Dex-IN, a product candidate under development for the treatment of post-operative pain; Dex-SL, a product candidate for the treatment of chronic pain, and Fadolmidine (Fado), a product candidate used by injection into the spine for pain associated with surgery or certain types of chronic pain and which the Company pursues as a topical product for local application to treat serious pain associated with nerve damage to local tissues (neuropathies), especially of the lower extremities, which can occur in diabetic patients.

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2400

Debt

Debt-to-Equity Ratio0.50%
Current Ratio1.59%
Quick Ratio1.35%

Price-To-Earnings

Trailing P/E Ratio-3.78993703225099
Forward P/E Ratio-3.74
P/E GrowthN/A

Sales & Book Value

Annual Sales$69.34 million
Price / Sales2.29
Cash FlowN/A
Price / CashN/A
Book Value$3.76 per share
Price / Book2.21

Profitability

Trailing EPS($2.19)
Net Income$-30,200,000.00
Net Margins-51.88%
Return on Equity-60.01%
Return on Assets-20.86%

Miscellaneous

Employees196
Outstanding Shares19,130,000

Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) posted its quarterly earnings results on Thursday, August, 10th. The specialty pharmaceutical company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.06. The specialty pharmaceutical company earned $16.93 million during the quarter, compared to the consensus estimate of $14.90 million. Recro Pharma had a negative net margin of 51.88% and a negative return on equity of 60.01%. View Recro Pharma's Earnings History.

Where is Recro Pharma's stock going? Where will Recro Pharma's stock price be in 2018?

6 analysts have issued twelve-month price objectives for Recro Pharma's stock. Their forecasts range from $6.50 to $20.00. On average, they expect Recro Pharma's share price to reach $14.42 in the next twelve months. View Analyst Ratings for Recro Pharma.

Who are some of Recro Pharma's key competitors?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:

  • Wayne B. Weisman J.D., Independent Chairman of the Board (Age 60)
  • Geraldine A. Henwood Ph.D., President, Chief Executive Officer, Director (Age 61)
  • Ryan D. Lake, Chief Financial Officer (Age 40)
  • Michael Celano, Chief Operating Officer (Age 58)
  • Jyrki Mattila M.D. Ph.D., Executive Vice President - Business Development (Age 62)
  • Randall Mack, Senior Vice President - Development, Secretary (Age 48)
  • Diane Myers, Senior Vice President - Regulatory and Quality (Age 51)
  • Fred Graff, Chief Commercial Officer
  • Stewart McCallum M.D., Chief Medical Officer
  • Alfred Altomari, Independent Director (Age 55)

Who owns Recro Pharma stock?

Recro Pharma's stock is owned by many different of retail and institutional investors. Top institutional investors include BROADFIN CAPITAL, LLC (15.31%), BROADFIN CAPITAL, LLC (15.31%), BROADFIN CAPITAL, LLC (14.15%), BROADFIN CAPITAL, LLC (13.14%), BROADFIN CAPITAL, LLC (13.14%) and Broadfin Capital LLC (12.73%). Company insiders that own Recro Pharma stock include Alfred Altomari, Donna Nichols, Healthcare Master Fun Broadfin, James E Flynn, Karen Flynn, Randall Mack, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp, Stewart Mccallum, Stonepine Capital Management, and Winston J Churchill. View Institutional Ownership Trends for Recro Pharma.

Who sold Recro Pharma stock? Who is selling Recro Pharma stock?

Recro Pharma's stock was sold by a variety of institutional investors in the last quarter, including Broadfin Capital LLC and Stonepine Capital Management LLC. Company insiders that have sold Recro Pharma company stock in the last year include Healthcare Master Fun Broadfin, James E Flynn, Scp Vitalife Partners (Israel), Scp Vitalife Partners Ii Lp and Stonepine Capital Management,. View Insider Buying and Selling for Recro Pharma.

Who bought Recro Pharma stock? Who is buying Recro Pharma stock?

Recro Pharma's stock was acquired by a variety of institutional investors in the last quarter, including Lyon Street Capital LLC, Schwab Charles Investment Management Inc., Wells Fargo & Company MN, Renaissance Technologies LLC, Strs Ohio, Deutsche Bank AG, Two Sigma Investments LP and BlackRock Inc.. Company insiders that have bought Recro Pharma stock in the last two years include Alfred Altomari, Donna Nichols, Healthcare Master Fun Broadfin, Karen Flynn, Randall Mack and Stewart Mccallum. View Insider Buying and Selling for Recro Pharma.

How do I buy Recro Pharma stock?

Shares of Recro Pharma can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of Recro Pharma stock can currently be purchased for approximately $8.30.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $158.75 million and generates $69.34 million in revenue each year. The specialty pharmaceutical company earns $-30,200,000.00 in net income (profit) each year or ($2.19) on an earnings per share basis. Recro Pharma employs 196 workers across the globe.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2400 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (REPH)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  161 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  272
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Recro Pharma (NASDAQ:REPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.832.752.802.83
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.42$12.13$13.50$14.75
Price Target Upside: 75.60% upside40.50% upside56.43% upside97.46% upside

Recro Pharma (NASDAQ:REPH) Consensus Price Target History

Price Target History for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ:REPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2018CIBCInitiated CoverageOutperform -> Outperform$19.00HighView Rating Details
2/13/2018OppenheimerInitiated CoverageOutperform$19.00HighView Rating Details
10/27/2017Piper Jaffray CompaniesReiterated RatingBuy$11.00N/AView Rating Details
7/31/2017Roth CapitalSet Price TargetBuy$20.00LowView Rating Details
6/14/2017Janney Montgomery ScottDowngradeBuy -> Fair Value$21.00 -> $6.50HighView Rating Details
3/27/2017AegisReiterated RatingBuy$11.00LowView Rating Details
11/29/2016HC WainwrightReiterated RatingBuy$19.00N/AView Rating Details
10/3/2016Brean CapitalInitiated CoverageBuy$21.00N/AView Rating Details
(Data available from 2/19/2016 forward)

Earnings

Recro Pharma (NASDAQ:REPH) Earnings History and Estimates Chart

Earnings by Quarter for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ REPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017($0.75)($0.48)$13.93 million$17.11 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.54)($0.48)$14.90 million$16.93 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.58)($0.42)$15.58 million$18.74 millionViewN/AView Earnings Details
3/6/2017Q4 2016($0.96)($0.81)$13.25 million$17.36 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.71)($0.50)$13.50 million$16.95 millionViewN/AView Earnings Details
8/11/2016Q2($0.78)($0.83)$18.70 million$17.30 millionViewN/AView Earnings Details
5/12/2016Q1($0.66)($0.71)$13.00 million$17.70 millionViewN/AView Earnings Details
3/24/2016Q4($0.43)$1.13$13.00 million$16.75 millionViewN/AView Earnings Details
11/13/2015Q3($0.20)($0.24)$16.54 millionViewN/AView Earnings Details
8/14/2015Q2 2015($0.17)$18.66 millionViewN/AView Earnings Details
5/13/2015Q115($0.52)($0.53)ViewN/AView Earnings Details
3/25/2015Q414($0.68)($0.45)ViewN/AView Earnings Details
11/10/2014Q314($0.51)($0.61)ViewN/AView Earnings Details
8/12/2014($0.25)($0.36)ViewN/AView Earnings Details
5/12/2014($0.36)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Recro Pharma (NASDAQ:REPH) Earnings Estimates

2018 EPS Consensus Estimate: ($2.53)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.52)($0.52)($0.52)
Q2 20181($0.54)($0.54)($0.54)
Q3 20181($0.79)($0.79)($0.79)
Q4 20181($0.68)($0.68)($0.68)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Recro Pharma (NASDAQ:REPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Recro Pharma (NASDAQ REPH) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 21.60%
Institutional Ownership Percentage: 61.88%
Insider Trades by Quarter for Recro Pharma (NASDAQ:REPH)
Institutional Ownership by Quarter for Recro Pharma (NASDAQ:REPH)

Recro Pharma (NASDAQ REPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/3/2018Scp Vitalife Partners (Israel)Major ShareholderSell12,964$8.88$115,120.32734,269View SEC Filing  
12/29/2017Scp Vitalife Partners Ii LpMajor ShareholderSell18,231$9.27$169,001.37View SEC Filing  
12/28/2017Scp Vitalife Partners (Israel)Major ShareholderSell1,980$9.44$18,691.20744,708View SEC Filing  
12/27/2017Scp Vitalife Partners Ii LpMajor ShareholderSell13,189$9.56$126,086.842,243,064View SEC Filing  
12/21/2017Healthcare Master Fun BroadfinMajor ShareholderSell76,000$9.87$750,120.00View SEC Filing  
12/13/2017Healthcare Master Fun BroadfinMajor ShareholderSell93,237$9.86$919,316.82View SEC Filing  
12/5/2017Healthcare Master Fun BroadfinMajor ShareholderSell100,000$10.00$1,000,000.00View SEC Filing  
11/30/2017Healthcare Master Fun BroadfinMajor ShareholderSell222,616$9.58$2,132,661.28View SEC Filing  
11/28/2017Healthcare Master Fun BroadfinMajor ShareholderSell47,549$9.64$458,372.36View SEC Filing  
11/24/2017Healthcare Master Fun BroadfinMajor ShareholderSell172,208$9.45$1,627,365.60View SEC Filing  
11/21/2017Healthcare Master Fun BroadfinMajor ShareholderSell102,440$9.50$973,180.00View SEC Filing  
6/14/2017James E FlynnInsiderSell110,447$6.39$705,756.33View SEC Filing  
6/13/2017James E FlynnMajor ShareholderSell32,447$6.59$213,825.73View SEC Filing  
6/12/2017James E FlynnMajor ShareholderSell10,000$6.74$67,400.00View SEC Filing  
6/8/2017James E FlynnInsiderSell62,868$7.06$443,848.08View SEC Filing  
5/12/2017Stonepine Capital Management,Major ShareholderSell510,000$7.40$3,774,000.00View SEC Filing  
5/11/2017Stonepine Capital Management,Major ShareholderSell244,629$7.65$1,871,411.85View SEC Filing  
5/4/2017Stonepine Capital Management,Major ShareholderSell217,308$7.70$1,673,271.60View SEC Filing  
3/16/2017Scp Vitalife Partners Ii LpMajor ShareholderSell44,977$8.00$359,816.002,276,571View SEC Filing  
2/17/2017Scp Vitalife Partners Ii LpMajor ShareholderSell9,983$7.59$75,770.972,292,899View SEC Filing  
2/16/2017Scp Vitalife Partners (Israel)Major ShareholderSell4,030$7.89$31,796.70772,714View SEC Filing  
12/16/2016Karen FlynnDirectorBuy800$6.71$5,368.00800View SEC Filing  
12/15/2016Alfred AltomariDirectorBuy1,500$6.55$9,825.001,500View SEC Filing  
12/13/2016Healthcare Master Fun BroadfinMajor ShareholderBuy650,000$6.00$3,900,000.00View SEC Filing  
8/16/2016Healthcare Master Fun BroadfinMajor ShareholderBuy390,000$7.50$2,925,000.00View SEC Filing  
5/31/2016Stewart MccallumInsiderBuy1,250$8.22$10,275.001,000View SEC Filing  
5/23/2016Randall MackVPBuy2,000$6.30$12,600.002,000View SEC Filing  
5/23/2016Scp Vitalife Partners (Israel)Major ShareholderSell2,503$6.30$15,768.90776,131View SEC Filing  
5/20/2016Scp Vitalife Partners (Israel)Major ShareholderSell6,260$6.46$40,439.60783,642View SEC Filing  
5/20/2016Winston J ChurchillDirectorSell58,331$7.91$461,398.21View SEC Filing  
5/19/2016Donna NicholsCAOBuy1,140$6.48$7,387.202,340View SEC Filing  
11/27/2015Scp Vitalife Partners Ii Lpmajor shareholderSell11,385$9.00$102,465.002,349,511View SEC Filing  
11/24/2015Scp Vitalife Partners (Israel)major shareholderSell4,393$9.00$39,537.00788,847View SEC Filing  
7/7/2015Healthcare Master Fun BroadfinMajor ShareholderBuy646,553$11.60$7,500,014.80View SEC Filing  
6/8/2015Geraldine HenwoodCEOBuy4,500$8.92$40,140.00View SEC Filing  
6/5/2015Charles GarnerCFOBuy2,000$8.50$17,000.00View SEC Filing  
12/2/2014Healthcare Master Fun BroadfinMajor ShareholderBuy241,338$2.50$603,345.00View SEC Filing  
5/15/2014Charles GarnerCFOBuy3,000$6.69$20,070.00View SEC Filing  
5/15/2014Donna NicholsCAOBuy1,200$6.66$7,992.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Recro Pharma (NASDAQ REPH) News Headlines

Source:
DateHeadline
Recro Pharma Inc (REPH) to Post FY2017 Earnings of ($2.43) Per Share, Oppenheimer ForecastsRecro Pharma Inc (REPH) to Post FY2017 Earnings of ($2.43) Per Share, Oppenheimer Forecasts
www.americanbankingnews.com - February 16 at 6:26 AM
Recro Pharma (REPH) Earns Outperform Rating from Analysts at CIBCRecro Pharma (REPH) Earns Outperform Rating from Analysts at CIBC
www.americanbankingnews.com - February 14 at 12:58 PM
Recro Pharma (REPH) Earns Outperform Rating from Analysts at UBS GroupRecro Pharma (REPH) Earns Outperform Rating from Analysts at UBS Group
www.americanbankingnews.com - February 13 at 8:40 PM
Recro Pharma Inc (REPH) Given Average Rating of "Buy" by BrokeragesRecro Pharma Inc (REPH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - February 13 at 7:48 PM
Recro Pharma (REPH) Now Covered by Analysts at OppenheimerRecro Pharma (REPH) Now Covered by Analysts at Oppenheimer
www.americanbankingnews.com - February 13 at 6:28 PM
$13.32 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter$13.32 Million in Sales Expected for Recro Pharma Inc (REPH) This Quarter
www.americanbankingnews.com - February 4 at 2:40 AM
Recro Pharma Announces Key Sales Team Additions Nasdaq:REPH - GlobeNewswire (press release)Recro Pharma Announces Key Sales Team Additions Nasdaq:REPH - GlobeNewswire (press release)
globenewswire.com - February 3 at 3:56 PM
 Brokerages Expect Recro Pharma Inc (REPH) Will Announce Earnings of -$0.74 Per Share Brokerages Expect Recro Pharma Inc (REPH) Will Announce Earnings of -$0.74 Per Share
www.americanbankingnews.com - February 2 at 5:10 PM
Recro Pharma Announces Key Sales Team AdditionsRecro Pharma Announces Key Sales Team Additions
finance.yahoo.com - February 2 at 9:47 AM
Recro Pharma (REPH) Reports Publication of Supportive Phase II IV Meloxicam DataRecro Pharma (REPH) Reports Publication of Supportive Phase II IV Meloxicam Data
www.streetinsider.com - January 18 at 1:37 PM
Recro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical PharmacologyRecro Pharma Announces Publication of Supportive Phase II IV Meloxicam Data in the Journal of Clinical Pharmacology
finance.yahoo.com - January 17 at 11:21 AM
Zacks: Brokerages Anticipate Recro Pharma Inc (REPH) Will Announce Earnings of -$0.79 Per ShareZacks: Brokerages Anticipate Recro Pharma Inc (REPH) Will Announce Earnings of -$0.79 Per Share
www.americanbankingnews.com - January 16 at 7:56 PM
After an Implosion, Reviewing Analyst Stocks Called to Rise 100% or MoreAfter an Implosion, Reviewing Analyst Stocks Called to Rise 100% or More
www.msn.com - January 16 at 3:35 PM
Recro Pharma Inc (REPH) Major Shareholder Sells $115,120.32 in StockRecro Pharma Inc (REPH) Major Shareholder Sells $115,120.32 in Stock
www.americanbankingnews.com - January 4 at 9:50 PM
Recro Pharma Announces Key Executive Promotions to the ... - GlobeNewswire (press release)Recro Pharma Announces Key Executive Promotions to the ... - GlobeNewswire (press release)
globenewswire.com - January 3 at 3:36 PM
UPDATE – Recro Pharma Announces Key Executive Promotions to the Financial TeamUPDATE – Recro Pharma Announces Key Executive Promotions to the Financial Team
finance.yahoo.com - January 3 at 3:36 PM
Recro Pharma Inc (REPH) Expected to Post Quarterly Sales of $13.32 MillionRecro Pharma Inc (REPH) Expected to Post Quarterly Sales of $13.32 Million
www.americanbankingnews.com - January 2 at 8:36 PM
Scp Vitalife Partners (Israel) Sells 1,980 Shares of Recro Pharma Inc (REPH) StockScp Vitalife Partners (Israel) Sells 1,980 Shares of Recro Pharma Inc (REPH) Stock
www.americanbankingnews.com - January 2 at 7:58 PM
Scp Vitalife Partners Ii Lp Sells 18,231 Shares of Recro Pharma Inc (REPH) StockScp Vitalife Partners Ii Lp Sells 18,231 Shares of Recro Pharma Inc (REPH) Stock
www.americanbankingnews.com - January 2 at 7:32 PM
-$0.79 Earnings Per Share Expected for Recro Pharma Inc (REPH) This Quarter-$0.79 Earnings Per Share Expected for Recro Pharma Inc (REPH) This Quarter
www.americanbankingnews.com - December 31 at 1:30 AM
Recro Pharma Inc (REPH) Major Shareholder Scp Vitalife Partners Ii Lp Sells 13,189 SharesRecro Pharma Inc (REPH) Major Shareholder Scp Vitalife Partners Ii Lp Sells 13,189 Shares
www.americanbankingnews.com - December 28 at 6:58 PM
ETFs with exposure to Recro Pharma, Inc. : December 26, 2017ETFs with exposure to Recro Pharma, Inc. : December 26, 2017
finance.yahoo.com - December 26 at 3:36 PM
Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017Recro Pharma, Inc. :REPH-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017
finance.yahoo.com - December 25 at 4:16 PM
Healthcare Master Fun Broadfin Sells 76,000 Shares of Recro Pharma Inc (REPH) StockHealthcare Master Fun Broadfin Sells 76,000 Shares of Recro Pharma Inc (REPH) Stock
www.americanbankingnews.com - December 22 at 5:54 PM
Insider Selling: Recro Pharma Inc (REPH) Major Shareholder Sells 93,237 Shares of StockInsider Selling: Recro Pharma Inc (REPH) Major Shareholder Sells 93,237 Shares of Stock
www.americanbankingnews.com - December 14 at 5:34 PM
Healthcare Master Fun Broadfin Sells 100,000 Shares of Recro Pharma Inc (REPH) StockHealthcare Master Fun Broadfin Sells 100,000 Shares of Recro Pharma Inc (REPH) Stock
www.americanbankingnews.com - December 7 at 5:26 PM
Comparing Recro Pharma (REPH) & PLx Pharma (PLXP)Comparing Recro Pharma (REPH) & PLx Pharma (PLXP)
www.americanbankingnews.com - December 5 at 9:34 AM
Recro Pharma, Inc. (REPH) Major Shareholder Healthcare Master Fun Broadfin Sells 47,549 SharesRecro Pharma, Inc. (REPH) Major Shareholder Healthcare Master Fun Broadfin Sells 47,549 Shares
www.americanbankingnews.com - November 30 at 8:20 PM
Recro Pharma, Inc. (REPH) Major Shareholder Sells $2,132,661.28 in StockRecro Pharma, Inc. (REPH) Major Shareholder Sells $2,132,661.28 in Stock
www.americanbankingnews.com - November 30 at 7:28 PM
$13.32 Million in Sales Expected for Recro Pharma, Inc. (REPH) This Quarter$13.32 Million in Sales Expected for Recro Pharma, Inc. (REPH) This Quarter
www.americanbankingnews.com - November 28 at 1:42 PM
Zacks: Analysts Expect Recro Pharma, Inc. (REPH) Will Post Earnings of -$0.78 Per ShareZacks: Analysts Expect Recro Pharma, Inc. (REPH) Will Post Earnings of -$0.78 Per Share
www.americanbankingnews.com - November 26 at 1:14 AM
Healthcare Master Fun Broadfin Sells 102,440 Shares of Recro Pharma, Inc. (REPH) StockHealthcare Master Fun Broadfin Sells 102,440 Shares of Recro Pharma, Inc. (REPH) Stock
www.americanbankingnews.com - November 24 at 4:24 PM
Recro Pharma, Inc. (REPH) Major Shareholder Sells $1,627,365.60 in StockRecro Pharma, Inc. (REPH) Major Shareholder Sells $1,627,365.60 in Stock
www.americanbankingnews.com - November 24 at 4:24 PM
Recro Pharma Secures $100 Million Credit Facility - GlobeNewswire (press release)Recro Pharma Secures $100 Million Credit Facility - GlobeNewswire (press release)
globenewswire.com - November 20 at 8:44 AM
Recro Pharma Secures $100 Million Credit FacilityRecro Pharma Secures $100 Million Credit Facility
finance.yahoo.com - November 20 at 8:43 AM
Recro Pharma, Inc. (REPH) Rating Lowered to Hold at Zacks Investment ResearchRecro Pharma, Inc. (REPH) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - November 18 at 8:18 PM
Recro Pharma, Inc. (REPH) Upgraded at Zacks Investment ResearchRecro Pharma, Inc. (REPH) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 15 at 7:14 AM
Recro Pharma Reports Third Quarter 2017 Financial ResultsRecro Pharma Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 12:22 PM
Recro Pharma reports 3Q lossRecro Pharma reports 3Q loss
finance.yahoo.com - November 9 at 12:22 PM
$13.93 Million in Sales Expected for Recro Pharma, Inc. (REPH) This Quarter$13.93 Million in Sales Expected for Recro Pharma, Inc. (REPH) This Quarter
www.americanbankingnews.com - November 9 at 12:00 PM
Recro Pharma, Inc. (REPH) Expected to Announce Earnings of -$0.75 Per ShareRecro Pharma, Inc. (REPH) Expected to Announce Earnings of -$0.75 Per Share
www.americanbankingnews.com - November 7 at 5:28 AM
Recro Pharma, Inc. (REPH) Given Average Rating of "Buy" by AnalystsRecro Pharma, Inc. (REPH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 5 at 1:40 PM
Recro Pharma, Inc. (REPH) Scheduled to Post Earnings on WednesdayRecro Pharma, Inc. (REPH) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 1 at 4:50 AM
Recro Pharma Reports Inducement Grants for New StaffRecro Pharma Reports Inducement Grants for New Staff
finance.yahoo.com - October 31 at 8:33 AM
Recro Pharma, Inc. (REPH) Rating Increased to Hold at Zacks Investment ResearchRecro Pharma, Inc. (REPH) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - October 31 at 6:58 AM
Recro Pharma (REPH) vs. Its Peers Critical ReviewRecro Pharma (REPH) vs. Its Peers Critical Review
www.americanbankingnews.com - October 27 at 7:14 AM
Recro Pharma, Inc. (REPH) Given Consensus Rating of "Buy" by AnalystsRecro Pharma, Inc. (REPH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - October 11 at 2:40 PM
Recro Pharma, Inc. (REPH) Lowered to "Sell" at Zacks Investment ResearchRecro Pharma, Inc. (REPH) Lowered to "Sell" at Zacks Investment Research
www.americanbankingnews.com - October 11 at 10:18 AM
Recro Pharma (REPH) Reports Phase III IV Meloxicam Clinical ... - StreetInsider.comRecro Pharma (REPH) Reports Phase III IV Meloxicam Clinical ... - StreetInsider.com
www.streetinsider.com - October 11 at 7:05 AM
Recro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual MeetingRecro Pharma Presents Phase III IV Meloxicam Clinical Efficacy Data in Patients Following Abdominoplasty at the 2017 American Society of Plastic Surgeons Annual Meeting
finance.yahoo.com - October 11 at 7:05 AM

SEC Filings

Recro Pharma (NASDAQ:REPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Recro Pharma (NASDAQ:REPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Recro Pharma (NASDAQ REPH) Stock Chart for Monday, February, 19, 2018

Loading chart…

This page was last updated on 2/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.